Barclays analyst Luke Sergott lowered the firm’s price target on Guardant Health (GH) to $115 from $130 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science and diagnostic tools group as part of a Q1 preview. Barclays likes the setup for the sector but says it is “not without risk.” Sentiment is at all-time lows and Barclays still believes in the “last-cut thesis (for the most part),” the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Oscar, Guardant, Redwire, Gap, AFLAC: Insider Moves Shock Wall Street
- William Blair health diagnostics analyst holds analyst/industry conference call
- Citi adds ‘upside 90-day catalyst watch’ on Guardant Health
- Guardant Health price target lowered to $90 from $110 at Evercore ISI
- Guardant Health added to Q2 Tactical Ideas List at Wells Fargo